Boston Scientific Gets CE Mark for Cardiac Defibrillator
December 29, 2007 - Boston Scientific Corp. received CE Mark approval for its LIVIAN cardiac resynchronization therapy defibrillator (CRT-D), which treats heart failure and is designed to help protect patients at risk of sudden cardiac death by monitoring heartbeats in heart failure patients and delivering small electrical impulses that may improve the heart’s pumping ability.
The LIVIAN CRT-D, which is available in high-energy and standard-energy models, enables clinicians to customize therapy based on a patient’s individual needs. The implantable is designed to improve a patient’s response to cardiac resynchronization therapy. LIVIAN also offers clinicians technology to help manage heart failure patients with frequent atrial arrhythmias.
“This next-generation CRT-D offers physicians in Europe and elsewhere even more flexibility for tailoring therapy to each patient,” said Jim Tobin, President and Chief Executive Officer of Boston Scientific. “It is a testament to our ongoing commitment to providing innovative solutions for the treatment of heart failure.”
This is the first approval of a Boston Scientific-branded cardiac rhythm management device to treat heart failure.
The LIVIAN CRT-D is pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.
For more information: www.bostonscientific.com